Ethyl-[2-[7-methoxy-5-[4-(morpholine-4-carbonyl)phenyl]-2,3-dihydro-1-benzofuran-2-yl]ethyl]carbamic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: Ethyl-[2-[7-methoxy-5-[4-(morpholine-4-carbonyl)phenyl]-2,3-dihydro-1-benzofuran-2-yl]ethyl]carbamic acid
• 英文别名: ethyl-[2-[7-methoxy-5-[4-(morpholine-4-carbonyl)phenyl]-2,3-dihydro-1-benzofuran-2-yl]ethyl]carbamic acid
• 化学式: C₂₅H₃₀N₂O₆
• 分子量: 454.5
• InChiKey: HNCBLTMOAVTKFT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  88.5
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• SUBSTITUTED 2,3-DIHYDROBENZOFURANYL COMPOUNDS AND USES THEREOF
  申请人：Karyopharm Therapeutics, Inc.

  公开号：EP2925750A1

  公开（公告）日：2015-10-07
• [EN] SUBSTITUTED 2,3-DIHYDROBENZOFURANYL COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS 2,3-DIHYDROBENZOFURANYLE SUBSTITUÉS ET LEURS UTILISATIONS
  申请人：KARYOPHARM THERAPEUTICS INC

  公开号：WO2014085607A1

  公开（公告）日：2014-06-05

  The invention generally relates to substituted 2,3-dihydrobenzofuranyl compounds, and more particularly to a compound represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.